The Food and Drug Administration on Jan. 31, 2020 approved Palforzia, Aimmune Therapeutics’ oral immunotherapy (OIT) treatment for peanut allergy… Read more »
An expert advisory panel has recommended that the Food and Drug Administration approve Aimmune Therapeutics’ oral immunotherapy (OIT) treatment for… Read more »
By extending the peanut biologic oral immunotherapy known as AR101 by 28 weeks, a new study finds that a majority… Read more »
The positive results of a pivotal Phase 3 study of a peanut biologic oral immunotherapy known as AR101 were published… Read more »
An FDA-approved treatment for food allergy is closer to reality after Aimmune Therapeutics announced that its large, Phase 3 trial… Read more »
All of the participants in the Phase II trial were able to tolerate nearly 2 peanut kernels at the end of two months.